Lanean...
EZH1/2 Inhibitors Favor ILC3 Development from Human HSPC-CD34(+) Cells
SIMPLE SUMMARY: It has been well-demonstrated that EZH1/2 enzymes are involved not only in tumor development and progression, but also in the regulation of normal hematopoiesis from CD34(+)-HSPC. Given the crucial role of NK cells in tumor immune surveillance, in this study, we investigated whether...
Gorde:
| Argitaratua izan da: | Cancers (Basel) |
|---|---|
| Egile Nagusiak: | , , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
MDPI
2021
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7830003/ https://ncbi.nlm.nih.gov/pubmed/33467134 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13020319 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|